• Mirunalini Ravichandran Department of Pharmacology,Mahatma Gandhi Medical COllege, Sri Balaji Vidhyapeeth university
  • Chandrasekaran M
  • Manime Kalai K


Objective: Osteoarthritis (OA), the most common joint disease has led to great morbidity and disability. Symptomatic slow acting drugs for OA, which
includes glucosamine sulfate, chondroitin sulfate, and diacerein provides symptom relief and structure-modifying effects in OA knee. Our aim was to
assess the efficacy and safety of chondroitin sulfate with glucosamine versus diacerein in Kellgren-Lawrence Grade II and III OA knee patients.
Methods: After approval from Institutional Human Ethics Committee and after getting written informed consent patients were randomized to
Group A: Tablet chondroitin sulfate (400 mg) with glucosamine (500 mg) combination thrice a day or Group B: Capsule diacerein 50 mg, twice a
day orally both after food. Out of 88 patients screened, 75 of them entered the study. A total of 15 patients failed to complete the study. Remaining
60 patients completed with 30 patients in each group. They were assessed for pain using visual analogue scale (VAS) from baseline and followed-up
at 3, 12, 24 weeks.
Results: Baseline characteristics in both the groups were matching without any significant difference. At 24 weeks there was reduction in VAS from
6.76 to 1.96 (71.01%) in Group A and from 6.8 to 3.53 (48.09%) in Group B. There was significant difference between the groups with Group A
significant over Group B in VAS. Thus, the effect of drug in Group A on pain reduction was greater than Group B.
Conclusion: The use of chondroitin sulfate with glucosamine combination resulted in improvement in VAS better than diacerein in OA knee.
Keywords: Osteoarthritis, Chondroitin sulfate with glucosamine combination, Diacerein, Visual analogue scale.


1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73(7):1323-30.
2. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22(3):363-88.
3. Ullal SD, Narendranath S, Kamath RK, Pai MR, Kamath SU, Amarnath DS. Prescribing pattern for osteoarthritis in a tertiary care hospital. J Clin Diagn Res 2010;4(3):2421-6.
4. Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK65646/. [Last cited on 2014 Sep 07].
5. Anandacoomarasamy A, March L. Current evidence for osteoarthritis treatments. Ther Adv Musculoskelet Dis 2010;2(1):17-28.
6. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16(4):494-502.
7. Huskisson EC. Measurement of pain. Lancet 1974;2(7889):1127-31.
8. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 2005;13(9):769-81.
9. Tukker A, Visscher TL, Picavet HS. Overweight and health problems of the lower extremities: Osteoarthritis, pain and disability. Public Health Nutr 2009;12(3):359-68.
10. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465-74.
219 Views | 650 Downloads
How to Cite
Ravichandran, M., C. M, and M. Kalai K. “EFFICACY OF CHONDROITIN SULFATE WITH GLUCOSAMINE VERSUS DIACEREIN IN GRADE II AND III OSTEOARTHRITIS KNEE: A RANDOMIZED COMPARATIVE STUDY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 4, July 2015, pp. 244-6, https://innovareacademics.in/journals/index.php/ajpcr/article/view/4106.
Original Article(s)